Ken Griffin Pfizer Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$27.7 - $31.39 $2.05 Million - $2.33 Million	-74,100 Reduced 0.61%	12,029,900 $348 Million
Q2 2024 Aug 14, 2024	BUY	$25.26 - $29.6 $64.6 Million - $75.7 Million	2,558,300 Added 26.8%	12,104,000 $339 Million
Q1 2024 May 15, 2024	BUY	$25.89 - $29.73 $38.6 Million - $44.4 Million	1,492,100 Added 18.53%	9,545,700 $265 Million
Q4 2023 Feb 14, 2024	SELL	$26.13 - $33.94 $145 Million - $189 Million	-5,555,700 Reduced 40.82%	8,053,600 $232 Million
Q3 2023 Nov 14, 2023	BUY	$32.09 - $37.51 $206 Million - $241 Million	6,418,200 Added 89.25%	13,609,300 $451 Million
Q2 2023 Aug 14, 2023	BUY	$36.12 - $41.79 $68.9 Million - $79.7 Million	1,908,300 Added 36.12%	7,191,100 $264 Million
Q1 2023 May 15, 2023	SELL	$39.39 - $51.28 $135 Million - $176 Million	-3,422,900 Reduced 39.32%	5,282,800 $216 Million
Q4 2022 Feb 14, 2023	SELL	$41.75 - $54.5 $56.9 Million - $74.2 Million	-1,361,800 Reduced 13.53%	8,705,700 $446 Million
Q3 2022 Nov 14, 2022	SELL	$43.76 - $53.42 $7.11 Million - $8.68 Million	-162,500 Reduced 1.59%	10,067,500 $441 Million

3,256

3.62B

77.2M

122M

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $140B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.